Piramal Pharma Ltd

Piramal Pharma Other Announcement

Piramal Pharma Limited informed exchanges that Niche99 has independently assigned it an ESG rating of 67.1 (ESG Band: Leader), without any company engagement.

Piramal Pharma Business Update

Piramal Pharma reported that the US FDA issued a Form-483 with 7 observations following a GMP inspection of its Morpeth, UK facility.

Piramal Pharma Other Announcement

Piramal Pharma Limited received an improved ESG rating of 65 from NSE Sustainability Ratings and Analytics. The rating was assigned voluntarily based on public disclosures.

Piramal Pharma Share Pledge

Deutsche Bank AG, acting as security agent, has disclosed the re-creation of a pledge over 98.4 million shares of Piramal Pharma Limited by the borrower.

Piramal Pharma Business Update

Piramal Pharma Limited released its Sustainability Report for FY2025-26, detailing the company's ESG performance across key pillars, including business resilience and operational sustainability.

Piramal Pharma Merger & Restructuring Worth ₹76 Cr

Piramal Pharma acquired an additional 40.67% stake in Yapan Bio for ₹76 Crore. This transaction increases its total holding to 74%, making Yapan Bio a subsidiary.

Value

₹76.00 Cr

Piramal Pharma Share Pledge

Deutsche Bank AG released 98,400,000 pledged equity shares of Piramal Pharma Limited, representing a 7.39% stake. The bank continues to hold 10.54% under pledge.

Piramal Pharma Merger & Restructuring

Piramal Pharma exercised a call option to acquire an additional 41% stake in Yapan Bio, becoming its majority shareholder with a 74% stake.

Piramal Pharma Business Update

Piramal Pharma has resumed operations at its Ahmedabad facility following the recent temporary suspension due to heavy rainfall. Operations are substantially restored with no material financial impact.

Piramal Pharma Annual General Meeting

Piramal Pharma Limited concluded its 6th Annual General Meeting, where shareholders approved all resolutions, including director re-appointments, auditor remuneration, and NCD issuance authority.

Piramal Pharma Investor Presentation: Key Takeaways

Piramal Pharma started FY27 with 17% revenue growth and 72% EBITDA expansion. Momentum was driven by CDMO recovery and power brands.

Piramal Pharma Results Update

Piramal Pharma Limited reported a consolidated revenue of ₹2,270 Crore for Q1 FY27, marking a 17% YoY increase. EBITDA for the quarter rose by 72% to ₹285 Crore.

Value

₹2,270 Cr

Piramal Pharma Q1 FY27 Results: Net Loss of ₹69.4 Cr, Loss Narrows

Piramal Pharma Ltd reported revenue from operations of ₹2,270 Cr (+17.4% YoY) and a net loss of ₹69.4 Cr for Q1 FY27.

Key figure

Net loss ₹69.4 Cr

Piramal Pharma Employee Stock Options

Piramal Pharma Limited announced the grant of 56,36,436 stock options to eligible employees under its Plan 2022. The options have an exercise price of Rs. 10 per share.

Piramal Pharma Adverse Business Impact

Piramal Pharma has temporarily suspended operations at its Ahmedabad facilities due to severe rainfall and flooding. The impact is currently under evaluation, with assets adequately insured.

Piramal Pharma Other Announcement

Piramal Pharma Ltd has submitted its quarterly shareholding pattern for the period ended June 30, 2026, in compliance with SEBI regulations.

Piramal Pharma Board Meeting Date

Piramal Pharma Ltd scheduled a Board Meeting for July 29, 2026. The board will consider and approve the unaudited financial results for the quarter ended June 30, 2026.

Piramal Pharma Regulatory Approval

Piramal Pharma disclosed that the US FDA has successfully completed its inspection of the Sellersville manufacturing facility. The clearance affirms compliance and operational continuity.

Piramal Pharma Business Update

Piramal Pharma filed its BRSR for FY 2025-26, detailing operations, employees, and subsidiaries. The report is a routine compliance disclosure with no new financial or operational event.

Piramal Pharma Annual General Meeting

Piramal Pharma Ltd announces its 6th AGM on 30 July 2026 and releases the FY 2025‑26 Annual Report. Shareholders may view it via QR code or the website.

Piramal Pharma Employee Stock Options

Piramal Pharma allotted 21,00,000 equity shares at Rs. 10 each to its ESOP Trust. The issuance supports the company's employee incentive plan and increases paid-up capital to ₹2.10 Crore.

Value

₹2.10 Cr

Piramal Pharma Business Update

Piramal Pharma received permanent revocation of closure directions for its Dahej site from GPCB. Operations continue normally, ensuring sustained manufacturing stability and environmental compliance.

Piramal Pharma Other Announcement

Piramal Pharma submitted its Annual Secretarial Compliance Report for the financial year 2025-26. The report confirms adherence to SEBI regulations with no adverse observations noted.

Piramal Pharma Business Update

Piramal Pharma received an Establishment Inspection Report from the US FDA for its Telangana facility. The inspection is successfully closed, ensuring regulatory compliance and operational continuity.

Piramal Pharma Business Update

US FDA concluded inspection of Piramal Pharma's Sellersville facility with three observations. Inspectors recommended VAI classification, with no findings relating to data integrity.

Piramal Pharma Other Announcement

Piramal Pharma Limited has updated the contact details for its Key Managerial Personnel (KMP) under SEBI Regulation 30(5). CFO Vivek Valsaraj and Company Secretary Maneesh Sharma are authorized for determining materiality and making stock exchange disclosures.

Piramal Pharma Management Change

Piramal Pharma Limited announced a leadership overhaul, appointing Maneesh Sharma as Company Secretary and Compliance Officer, effective April 29, 2026. The board also approved the re-appointment of Nandini Piramal and Peter DeYoung as Executive Directors, alongside Independent Directors Sridhar Gorthi and Peter Stevenson. These changes ensure long-term governance stability and executive continuity.

Execution

36-60 months

Piramal Pharma Results Update

Piramal Pharma Limited announced its FY26 results, reporting revenue of ₹8,869 Crore. Performance was impacted by inventory destocking and slower inflows, although the company maintained a strong quality track record with zero OAI. Management remains optimistic for FY27 growth driven by the CDMO and CHG businesses.

Value

₹8,869 Cr

Piramal Pharma Q4 FY26 Results: Net Loss of ₹8.8 Cr

Piramal Pharma Ltd reported revenue from operations of ₹2,752 Cr (-0.1% YoY) and a net loss of ₹8.8 Cr for Q4 FY26.

Key figure

Net loss ₹8.8 Cr

Piramal Pharma Financial Results

Piramal Pharma Limited reported its FY2026 audited financial results, showing standalone annual revenue of ₹4,782.01 Crore and PAT of ₹700.01 Crore. The Board also approved the re-appointment of Ms. Nandini Piramal as Chairperson and Mr. Peter DeYoung as Executive Director, alongside shifting the company's registered office and appointing a new Company Secretary.